Company intelligence / Profile preview
Clovis Oncology
Boulder, Colorado, United Statesclovisoncology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Clovis Oncology developed Rubraca (rucaparib) for ovarian and prostate cancer, which received FDA approval. The company also had FAP-2286, a peptide-targeted radionuclide therapy candidate in Phase 1/2 trials. The company filed for bankruptcy in December 2022.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesPeptide-targeted radionuclide therapy (PTRT)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Clavis PharmaBristol-Myers Squibb (Opdivo combination trials)
Beyond the preview
Go deeper on Clovis Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clovis Oncology.